Enbrel® was the first-approved biologic for both continuous and intermittent PsO therapies.1
The recommended dose of Enbrel® for adult patients with plaque PsO is2:
Treatment with Enbrel® should continue for up to 24 weeks until remission is achieved. Continuous therapy beyond 24 weeks may be appropriate for some adult patients with PsO. Treatment should be discontinued in patients with PsO who show no response after 12 weeks. If re-treatment with Enbrel® is indicated, the same guidance on treatment duration should be followed. The dose should be 25 mg BIW or 50 mg QW.2
BIW, twice a week; PsO, psoriasis; QW, once a week; TNFR, tumour necrosis factor receptor.
Enbrel® is a soluble tumour necrosis factor receptor fusion protein
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered Medical Practitioner*, please visit
https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.
PP-UNP-IND-0012 July 2022